Understanding Neoadjuvant Chemotherapy Utilization And Perioperative Morbidity
Let's dive into the details surrounding Neoadjuvant Chemotherapy Utilization And Perioperative Morbidity. Read the article: http://onlinelibrary.wiley.com/doi/10.1111/bju.12585/abstract Johnson DC, Nielsen ME, Matthews J, et al.
Key Takeaways about Neoadjuvant Chemotherapy Utilization And Perioperative Morbidity
- Dr Mark Kris discusses the history of and considerations for using
- Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Arlene Siefker-Radtke, ...
- In this episode of OncoDaily, Dr. Petros Grivas joins host Chandler Park to discuss the groundbreaking NIAGARA study presented ...
- Taking the con side in a point-counterpoint debate, Alan H. Bryce, MD, argues against offering
- Tyler Stewart, MD, University of California, San Diego, CA, comments on results from the Phase III KEYNOTE-B15 trial ...
Detailed Analysis of Neoadjuvant Chemotherapy Utilization And Perioperative Morbidity
Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, gives an overview of the Phase III NIAGARA trial ... Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor ... A. Edward Yen, MD, summarizes research on
Dr. Scott GIlbert speaks on
That wraps up our extensive overview of Neoadjuvant Chemotherapy Utilization And Perioperative Morbidity.
